홈MCP워크벤치Skills
홈워크벤치알림마이페이지
Huagongshe 오픈 프로젝트:[email protected]AI 접속: llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.7.8
돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 89949생성일: 2026년 11월 2일

Abnormal Cannabidiol

ABN-CBD · Abn CBD,AbnCBD · Cannabidiol, Abnormal · Abnormal Cannabidiol (Abn-CBD) · Abn-CBD (Abnormal Cannabidiol) · 1-Hydroxy-3-n-Pentylcannabidiol · 4-(p-Mentha-1,8-dien-3-yl)-5-pentylresorcinol · 8-dien-3-yl-5-pentyl-4-p-mentha-(-)-(e)-resorcino

https://huagongshe.com/ko/chemical/89949

Abnormal Cannabidiol 분자 구조식

식별자 및 물리적 특성

CAS No.22972-55-0
분자식C21H30O2
평균 분자량314.5 g/mol
단동위원소 질량314.2245802 g/mol
SMILESC=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(O)cc1CCCCC
InChIKeyYWEZXUNAYVCODW-RBUKOAKNSA-N
PubChem CID89949
ChEMBLCHEMBL499876
ChEBICHEBI:197013
DTXSIDDTXSID10945675

화학 및 물리적 성질

XLogP6.5
극성 표면적40.5
수소 결합 공여자 수2
수소 결합 수용자 수2
회전 가능 결합 수6
무거운 원자 수23
형식 전하0
복잡도426
Endocrine DisruptorsPotential endocrine disrupting compound
끓는 점446.4±45.0 °C(Predicted)
밀도1.025±0.06 g/cm3(Predicted)
저장 조건Desiccate at -20°C
용해도Soluble in methyl acetate (supplied pre-dissolved - 5mg/ml)
물리적 상태가루
pKa(산도 계수)9.94±0.45(Predicted)

안전 및 규제

신호 어Danger
유해·위험 문구암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H225

용도

개요

Abnormal cannabidiol is a synthetic cannabidiol agonist of GPR55 (EC50 = 2.5 μM in a GTPγS binding assay). It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 μM for both in GTPγS binding assays). It is also a full agonist at GPR18, with an EC50 value of 0.835 μM for inducing p44/42 MAPK phosphorylation in HEK293 cells expressing GPR18. Abnormal cannabidiol increases migration of BV-2 microglial cells (EC50 = 0.6 μM). It induces endothelium-dependent vasodilation via a CB1-CB2-NO-independent mechanism and inhibits vasoconstriction induced by endothelin 1 (ET-1; ) in retinal arterioles, an effect that can be blocked by the calcium-sensitive potassium channel blocker apamin . Abnormal cannabidiol also decreases blood pressure in anesthetized rats when administered intravenously at a dose of 20 μg/g or when administered directly into the rostral ventrolateral medulla at 0.4 and 0.8 μg.